eXoZymes, Inc.

What they do

eXoZymes engineers enzymes with the aid of artificial intelligence that function in bioreactors outside living cells, which the company calls exozyme biosolutions. It states this cell-free approach converts feedstocks into chemicals without the scaling constraints it attributes to whole-cell synthetic biology. Management says it is targeting pharmaceutical and nutraceutical compounds first, and has also demonstrated isobutanol for Sustainable Aviation Fuel. The company reports one operating segment and no separate reportable segments under ASC 280.

Revenue drivers

• License or product sales of exozyme biosolutions — The company describes potential commercialization via productized compounds and possible licensing, but reported total operating income of $0 for 2025 and the six months ended June 30, 2026.
• Pharmaceutical and nutraceutical compounds — These are the first target markets management names, citing natural products and natural-product-inspired small molecules such as active pharmaceutical ingredients; no revenue has been recognized to date.
• Biofuels feedstock (isobutanol) — Isobutanol for Sustainable Aviation Fuel is cited as a demonstrated application through publications, use cases and pilot projects with potential partners, not as a contracted revenue line.

Recent performance

Revenue was $0 in 2025 and in the six months ended June 30, 2026, versus no comparative revenue. The 2025 net loss was $9.16 million, or $9.26 million before a $105,205 income tax benefit, compared with a $5.86 million net loss in 2024; diluted EPS was -$1.09 in 2025 versus -$0.89 in 2024. For the six months ended June 30, 2026, the net loss was $5.25 million versus $4.22 million a year earlier, with research and development costs up 85.7% to $2.56 million. Total operating costs for the first half of 2026 were $5.34 million, up 18.7%, while general and administrative costs fell 10.9% to $2.78 million. At June 30, 2026 the company reported total assets of $8.0 million, total liabilities of $4.3 million, shareholder equity of $3.7 million and cash and equivalents of $5.7 million.

Strategy

Management says it will focus first on pharmaceutical and nutraceutical markets where it believes its core technology fits and compounds are highly valuable. It frames the cell-free exozyme approach as avoiding the scale-up problems it associates with live-cell synthetic biology. Spending is rising on research and development and on staff, including administrative hires not funded by grants, following the 2024 IPO and the associated Nasdaq and SEC compliance costs. The company states it anticipates needing additional capital over time to fund product development and commercialization.

Risks

• Pre-revenue, limited operating history — Founded in 2019, the company reported no operating income in 2025 or the first half of 2026 and says it does not expect revenue or net income until it commercializes its first products.
• Need for additional capital and dilution — Management states the business will require additional capital over time and that this capital may be difficult to obtain, potentially restricting operations and diluting stockholders.
• Technology still at lab scale — The 10-K states the technology is still largely in development and the limited number of products is being produced only at lab scale quantities.
• No assurance of commercial viability — The company says its development efforts may never produce commercially viable processes or products, achieve market acceptance, or generate sustaining revenue, and that it may never recover research and development and start-up expenses.

Outlook

Management does not provide revenue or earnings guidance, stating it does not expect revenue or net income until its first products are commercialized over a significant period. The stated near-term priority is developing and productizing compounds for the pharmaceutical and nutraceutical markets while the exozyme platform is developed further. The company acknowledges it will need additional capital to implement its long-term product development and commercialization plan.